NAVERIS is a clinical stage company whose mission is to improving patient outcomes through early cancer detection.
NAVERIS is using the power of detecting circulating tumor DNA to develop and commercialize pioneering products for the early detection of cancer.
Naveris uses disruptive technology to develop liquid biopsy blood tests to detect viral associated cancers, which comprise approximately 40% of human cancer.
Our liquid biopsy tests use proprietary technology to capture and analyze DNA in blood for early cancer detection in the real time monitoring of response in patients undergoing treatment, and early detection of cancer recurrence for patients in remission. We have the ability to distinguish cancer associated DNA from other sources, the ability of unprecedented accuracy , and our test is economical and highly reproducible .